BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31017664)

  • 21. Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab.
    Koukourakis MI; Giatromanolaki A; Sheldon H; Buffa FM; Kouklakis G; Ragoussis I; Sivridis E; Harris AL;
    Clin Cancer Res; 2009 Nov; 15(22):7069-76. PubMed ID: 19887481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: A predictive marker and promising target for radiosensitization.
    Kudryavtsev VA; Khokhlova AV; Mosina VA; Selivanova EI; Kabakov AE
    PLoS One; 2017; 12(3):e0173640. PubMed ID: 28291803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.
    Seyedin SN; Hasibuzzaman MM; Pham V; Petronek MS; Callaghan C; Kalen AL; Mapuskar KA; Mott SL; Spitz DR; Allen BG; Caster JM
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):81-92. PubMed ID: 32036006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
    Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study.
    Ohri N; Dawson LA; Krishnan S; Seong J; Cheng JC; Sarin SK; Kinkhabwala M; Ahmed MM; Vikram B; Coleman CN; Guha C
    J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27377923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
    Tintelnot J; Stein A
    World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer.
    Kinzel L; Ernst A; Orth M; Albrecht V; Hennel R; Brix N; Frey B; Gaipl US; Zuchtriegel G; Reichel CA; Blutke A; Schilling D; Multhoff G; Li M; Niyazi M; Friedl AA; Winssinger N; Belka C; Lauber K
    Oncotarget; 2016 Jul; 7(28):43199-43219. PubMed ID: 27259245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
    Thomas J; Leal A; Overman MJ
    Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening and Validation of Molecular Targeted Radiosensitizers.
    Willers H; Pan X; Borgeaud N; Korovina I; Koi L; Egan R; Greninger P; Rosenkranz A; Kung J; Liss AS; Parsels LA; Morgan MA; Lawrence TS; Lin SH; Hong TS; Yeap BY; Wirth LJ; Hata AN; Ott CJ; Benes CH; Baumann M; Krause M
    Int J Radiat Oncol Biol Phys; 2021 Dec; 111(5):e63-e74. PubMed ID: 34343607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanotechnology: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(19):1-43. PubMed ID: 23074489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.
    Llosa NJ; Luber B; Siegel N; Awan AH; Oke T; Zhu Q; Bartlett BR; Aulakh LK; Thompson ED; Jaffee EM; Durham JN; Sears CL; Le DT; Diaz LA; Pardoll DM; Wang H; Housseau F; Anders RA
    Cancer Immunol Res; 2019 Oct; 7(10):1574-1579. PubMed ID: 31439614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review.
    Zaborowski AM; Winter DC; Lynch L
    Br J Cancer; 2021 Nov; 125(10):1341-1349. PubMed ID: 34302062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.
    Yaghoubi N; Soltani A; Ghazvini K; Hassanian SM; Hashemy SI
    Biomed Pharmacother; 2019 Feb; 110():312-318. PubMed ID: 30522017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin: A Promising Radiosensitizer in Neoadjuvant Rectal Cancer Treatment.
    Georgopoulos NS; Tolia M; Mauri D; Kamposioras K; Charalampakis N; Tsoukalas N; Gkantaifi A
    Rev Recent Clin Trials; 2023; 18(3):172-180. PubMed ID: 37132307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.
    Williams TM; Flecha AR; Keller P; Ram A; Karnak D; Galbán S; Galbán CJ; Ross BD; Lawrence TS; Rehemtulla A; Sebolt-Leopold J
    Mol Cancer Ther; 2012 May; 11(5):1193-202. PubMed ID: 22411900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
    Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
    JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Colorectal Cancer Immunotherapy: Options and Strategies.
    Johdi NA; Sukor NF
    Front Immunol; 2020; 11():1624. PubMed ID: 33042104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.